Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M167,829Revenue (TTM) $M49,634Net Margin (%)13.7Altman Z-Score2.4
Enterprise Value $M194,358EPS (TTM) $2.9Operating Margin %17.1Piotroski F-Score5
P/E(ttm)25.4Beneish M-Score-2.7Pre-tax Margin (%)15.8Higher ROA y-yN
Price/Book2.310-y EBITDA Growth Rate %-0.7Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %-3.8Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow19.9y-y EBITDA Growth Rate %-8.7ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.9PEG--ROE % (ttm)9.1Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,376ROIC % (ttm)7.5Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKen Fisher 2016-12-31 Add$67.59 - $79.13
($72.39)
$ 70.65-2%Add 0.16%6,074,870
NVSDodge & Cox 2016-09-30 Reduce-0.06%$78.27 - $83.51
($81.32)
$ 70.65-13%Reduce -1.77%43,581,886
NVSKen Fisher 2016-09-30 Reduce-0.05%$78.27 - $83.51
($81.32)
$ 70.65-13%Reduce -4.69%6,065,150
NVSTweedy Browne 2016-09-30 Reduce-0.03%$78.27 - $83.51
($81.32)
$ 70.65-13%Reduce -5.85%220,115
NVSJohn Rogers 2016-09-30 Reduce$78.27 - $83.51
($81.32)
$ 70.65-13%Reduce -6.10%13,914
NVSMario Gabelli 2016-09-30 Add$78.27 - $83.51
($81.32)
$ 70.65-13%Add 4.16%6,265
NVSDodge & Cox 2016-06-30 Reduce-0.05%$71.4 - $82.51
($77.03)
$ 70.65-8%Reduce -1.53%44,366,511
NVSTweedy Browne 2016-06-30 Reduce-0.01%$71.4 - $82.51
($77.03)
$ 70.65-8%Reduce -1.63%233,783
NVSKen Fisher 2016-06-30 Add0.01%$71.4 - $82.51
($77.03)
$ 70.65-8%Add 1.22%6,363,641
NVSMario Gabelli 2016-06-30 Reduce$71.4 - $82.51
($77.03)
$ 70.65-8%Reduce -12.38%6,015
NVSJohn Rogers 2016-06-30 Add$71.4 - $82.51
($77.03)
$ 70.65-8%Add 11.45%14,818
NVSTweedy Browne 2016-03-31 Reduce-0.01%$71.11 - $86.21
($76.1)
$ 70.65-7%Reduce -1.87%237,664
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 70.65-7%Add 1.59%6,287,099
NVSTom Gayner 2016-03-31 Buy 0.01%$71.11 - $86.21
($76.1)
$ 70.65-7%New holding3,700
NVSMario Gabelli 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 70.65-7%Reduce -7.10%6,865
NVSDodge & Cox 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 70.65-7%Reduce -0.12%45,054,916
NVSJohn Rogers 2016-03-31 Add$71.11 - $86.21
($76.1)
$ 70.65-7%Add 18.01%13,296
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 70.65-20%Reduce -1.35%45,107,085
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 70.65-20%Reduce -3.15%27,643
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 70.65-20%Reduce -2.74%242,201
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15371view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    2 Top Health Care Dividend Stocks Jan 12 2017 
    7 Stocks With Low P/S Ratios Jan 11 2017 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
    The Pharmaceutical Sector Looks Attractive Oct 12 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novartis Is Surviving Oct 03 2016 
    A Double Dose of Trouble at Novartis Sep 22 2016 
    Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 

    More From Other Websites
    Novartis’s 4Q16 Earnings: What Is Expected? Jan 20 2017
    Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint? Jan 20 2017
    Novartis CEO: Trump Understands Value of Drug Innovation Jan 20 2017
    CSL shares jump on profit upgrade Jan 19 2017
    CSL shares rally on profit guidance hike Jan 18 2017
    Mallinkrodt Shares Tank Despite $100 Million FTC Deal Jan 18 2017
    Novartis CEO Discusses Impact of Trump on Drug Industry Jan 18 2017
    Trump tax cuts could mean more Novartis investment in U.S. Jan 18 2017
    Trump tax cuts could mean more Novartis investment in U.S Jan 18 2017
    Trump tax cuts could mean more Novartis investment in U.S Jan 18 2017
    How Did Novartis’s Innovative Medicines Segment Perform? Jan 17 2017
    How Is Novartis’s Revenue Trending? Jan 16 2017
    How Did Novartis Perform in 3Q16? Jan 16 2017
    5 Trump-Proof Pharma Dividends Up To 5.3% Jan 16 2017
    How Does Novartis’s Valuation Compare to Peers? Jan 16 2017
    Novartis to Conduct Trial on Obese, Type II Diabetes Patients Jan 13 2017
    [$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs Jan 13 2017
    Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit Jan 13 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)